Triomics builds AI-powered solutions for oncology, transforming unstructured electronic health records (EHR) into structured, actionable datasets. The platform reads across entire patient records—including notes, pathology, imaging, and molecular data—to deliver accurate, cited insights directly into clinical workflows.
Designed specifically for cancer centers, Triomics supports key use cases such as patient trial matching, visit preparation, and cancer registry curation. Its AI agents reason at the patient level, enabling teams to act on comprehensive, evidence-based summaries before the point of care.
The company emphasizes clinical depth, traceability, and seamless integration with existing systems like Epic, OncoEMR, and iKnowMed. Every output includes source citations, ensuring transparency and auditability, and the platform is approved on the Epic App Marketplace.
Triomics is backed by leading investors in AI and healthcare, including Battery Ventures, Lightspeed, Nexus, and Y Combinator, and is used by multiple NCI-designated cancer centers across the U.S.